Abstract
In a prospective study 46 patients with far advanced, surgically not totally resectable pancreatic carcinomas underwent a multimodal, complementary therapy. All patients received: loco-regional radiofrequency deep hyperthermia (13.56 MHz), enzyme-therapy (Kreon®, Wobenzym®), anti-hormonal therapy (tamoxifen, flutamid, LH-RH-Analoga), immunomodulating agents (thymus-peptides, mistletoe extract, cimetidine, prostaglandine-antagonists), differentiating agents (high-dose vitamin A-E-palmitate, alpha-hydroxycalciferol, coumarines), endogenous hyperpyrexia with a mixed bacterial vaccine (Vaccineurin®). Some patients in progress under this regimen were treated with 5-FU, Mitomycin C, α-Interferon, combined with loco-regional deep hyperthermia. Results: Median overall survival was 10.8 months with a 5-year-survival rate of 9 %. Most patients experienced partially excellent improvement in quality of life (gain of appetite and weight, pain relief, improvement in general condition) and clinical criteria (reduction of ascites, jaundice and tumor mass, destruction of metastatic focuses, clinical chemistry and decrease of tumor marker CEA and CA 19-9).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
